Real-world evidence has moved from a supporting role to a strategic imperative. Regulators are expanding its use in submissions. Payers are demanding it for reimbursement. HTA bodies are building it into evaluation frameworks. For pharma, biotech, and data science professionals, the question is no longer whether RWE matters. It is where to go to stay ahead of how it is being applied.

The 2026 conference calendar offers a strong set of options. Some are dedicated RWE forums. Others embed RWE deeply within HEOR, market access, and pharmacoepidemiology programs. Each serves a different audience and a different purpose.

Below are the ten best RWE conferences to attend in 2026, selected for topic depth, audience quality, and strategic value.

The 10 Best RWE Conferences to Attend in 2026

1. RWE Connect 2026 (14–15 October 2026, Boston, USA)

Best overall choice for RWE strategy, data, analytics, and outcome-focused professionals

RWE Connect 2026 is purpose-built for professionals whose work centres on real-world evidence. Held in Boston — home to one of the world’s most concentrated life sciences ecosystems — it brings together pharma leaders, data scientists, regulatory experts, market access teams, HEOR professionals, and technology innovators under one agenda.

Why RWE Connect stands out:

• Integrated track design. The conference covers regulatory science, data and analytics, and technology and innovation across a unified programme — avoiding the fragmentation that affects broader events. Attendees move between sessions without losing strategic context.
• Senior speaker profile. Confirmed speakers include heads of RWE and HEOR from Boehringer Ingelheim, Gilead Sciences, BioMarin, Novo Nordisk, Alcon, Bayer, and Celcuity, alongside academic and consulting voices from institutions including Otsuka Precision Health and Arcadia.
• Outcome-driven formats. The exclusive Partnering Lounge enables structured 1:1 meetings. An RWE Innovation Showcase, Startup Pavilion, and Hands-On Masterclass Workshops move the programme beyond passive attendance.

Who should attend RWE Connect 2026:

• RWE, HEOR, and epidemiology leads at pharma and biotech
• Data science, AI, and analytics professionals in life sciences
• Market access, medical affairs, and regulatory teams
• CROs, consultants, and RWD solution providers

If you attend one RWE conference in 2026, RWE Connect delivers the most focused, senior, and commercially relevant environment in the calendar.

2. ISPOR 2026 (17–20 May 2026, Philadelphia, USA)

Best for HEOR, policy, and value framework professionals

ISPOR 2026, themed “HEOR at the Forefront of Policy, Access, and Value,” attracted over 4,500 stakeholders to the Pennsylvania Convention Center in May. The programme covered AI-enabled workflows, RWE strategy across the drug development lifecycle, patient-centred evidence generation, and the implications of pricing reform — including the Inflation Reduction Act and international reference pricing.

RWE featured prominently in sessions on regulatory submissions, market access strategy, and lifecycle management. ISPOR 2026 also reinforced a broader theme: HEOR is shifting from a reimbursement function to a strategic capability across development and commercialisation.

Strengths: Scale, scientific rigour, global audience, policy depth.

Considerations: Broad scope across HEOR means RWE is one stream among many. RWE-specific decisions require heavy session planning.

3. HTAi 2026 Annual Meeting (6–10 June 2026, Istanbul, Turkey)

Best for HTA bodies, policy makers, and market access professionals working across borders

The HTAi 2026 Annual Meeting, themed “HTA as a System Shaper,” brought together the global health technology assessment community in Istanbul. The programme focused on evidence-informed decision-making, equitable access, and the integration of RWE into HTA evaluation frameworks — including discussion of joint clinical assessments under EU HTA regulation.

For professionals working on how real-world data informs product access decisions — particularly in Europe and Asia Pacific — HTAi is one of the few forums where HTA bodies, regulators, and industry engage on equal footing.

Strengths: HTA community depth, cross-border policy discussion, and regulatory/payer access.

Considerations: Limited commercial networking; strongest value for teams working directly on access strategy and HTA submissions.

4. GetReal Institute Annual Conference 2026 (29–30 June 2026, Utrecht, Netherlands)

Best for RWE methods, regulatory alignment, and European HTA decision-making

The GetReal Institute Annual Conference is the leading European multistakeholder forum dedicated entirely to advancing real-world evidence. The 2026 edition focused on translating real-world data into evidence that meets the expectations of regulators and HTA bodies — covering fit-for-purpose study design, data quality standards, AI integration, and the practical challenges introduced by the European Health Data Space.

Attendees include researchers, regulators, HTA representatives, patient advocates, and industry professionals working on European RWE adoption. The format prioritises collaborative discussion over broadcast sessions.

Strengths: Methodological rigour, European regulatory alignment, multistakeholder engagement, non-commercial environment.

Considerations: Smaller scale; not designed for commercial interactions or partner evaluation.

5. ISPE 42nd Annual Meeting / ICPE 2026 (29 August–2 September 2026, Milan, Italy)

Best for pharmacoepidemiology, drug safety, and real-world data methodology

The International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) is the flagship annual event of the International Society for Pharmacoepidemiology. The 2026 edition, themed “Unlocking the Power of Pharmacoepidemiology to Improve Patient Health,” is being held at the Allianz MiCo Convention Center in Milan, with over 2,000 participants expected.

For professionals working at the intersection of RWD methods, post-market surveillance, benefit-risk assessment, and regulatory science, ICPE 2026 offers the deepest scientific programme in the calendar. Sessions cover causal inference, study design, pharmacovigilance, and real-world evidence applications across therapeutic areas.

Strengths: Scientific depth, methodological focus, global pharmacoepidemiology community.

Considerations: Academic orientation; limited commercial and partnership activity.

6. 14th IMPACCT Real-World Evidence Summit (October 2026, Boston, USA)

Best for lifecycle RWE strategy and drug development professionals

The IMPACCT Real-World Evidence Summit, organised by Hanson Wade, has built a 14-year record as the industry’s most focused gathering for pharma and biotech professionals working on RWE across the drug development lifecycle. The 2026 edition returns to Boston in October.

Past editions have drawn senior attendees from AstraZeneca, Pfizer, AbbVie, Biogen, Alexion, and Boehringer Ingelheim. Sessions address data quality, AI and predictive modelling in RWE analysis, regulatory submission strategy, and integrated evidence planning.

Strengths: Senior industry audience, actionable case studies, cross-functional networking.

Considerations: Specific dates not yet confirmed; registration interest lists open now.

7. DIA Real-World Evidence Conference 2026 (19–20 October 2026, North Bethesda, USA)

Best for regulatory-focused RWE and FDA/EMA engagement

The Drug Information Association’s annual RWE conference is one of the most regulatory-forward events in the calendar. The 2026 edition, themed “Translating Insights into Real-World Value,” will be held at the Bethesda North Marriott Hotel and Conference Center.

Confirmed speakers include leaders from the FDA, EMA, Amgen, AstraZeneca, Pfizer, IQVIA, RTI Health Solutions, and Duke-Margolis Institute for Health Policy. Sessions cover data quality, governance, evolving regulatory standards for RWD, study design, and collaborative research models.

Strengths: Regulatory depth, agency engagement, governance and standards focus.

Considerations: Two-day format; strongest value for regulatory affairs and evidence submission teams.

8. ISPOR Healthcare Investment Summit 2026 (22–23 September 2026, San Francisco, USA)

Best for investors, developers, and value strategists at the intersection of HEOR and capital

The ISPOR Healthcare Investment Summit brings together biopharma investors, drug developers, policy leaders, and HEOR professionals to examine how products are evaluated, priced, and adopted in an evolving policy environment. The 2026 edition takes place in San Francisco.

For RWE professionals engaged in value demonstration, pre-launch evidence planning, or commercial strategy, this summit connects evidence generation directly with investment and access outcomes.

Strengths: Investor/industry crossover, value strategy, commercial evidence framing.

Considerations: Not a scientific or methods forum; most valuable for commercially oriented RWE teams.

9. ISPOR Europe 2026 (8–11 November 2026, Vienna, Austria)

Best for European HEOR, HTA, and market access professionals

ISPOR Europe is the Society’s largest annual gathering in the region, drawing 5,000+ attendees from across academia, industry, HTA bodies, payers, and regulators. The 2026 edition in Vienna covers HTA, RWE generation and application, pricing, and reimbursement strategies across European markets.

For teams working on EU HTA regulation, joint clinical assessments, or multi-market access strategies, ISPOR Europe provides a scale and breadth of engagement that few other events can match.

Strengths: European HTA community depth, policy and market access scope, scale.

Considerations: RWE is one stream within a large, multidisciplinary programme.

10. GlobalBSG Pharma Pricing & Market Access Innovation Summit (12–13 November 2026, Vienna, Austria)

Best for senior pricing and access executives exploring value demonstration strategies

The GlobalBSG summit brings together senior executives in pricing, HEOR, market access, payer engagement, and regulatory affairs. The 2026 edition in Vienna focuses on affordability, value demonstration, and access innovation across international markets.

For RWE teams whose work connects directly to pricing decisions and reimbursement frameworks, this summit provides a senior forum for commercial-stage evidence strategy discussions.

Strengths: Senior commercial audience, pricing/access integration, international scope.

Considerations: Smaller event; limited scientific or methods content.

Why RWE Connect 2026 Needs to Be on Your Calendar

The RWE field has a signal-to-noise problem. Most conferences that claim to cover real-world evidence are broad pharma events with one RWE track buried between six others. The senior people you actually need to meet are spread thin across three days and four simultaneous session streams.

RWE Connect is built differently. Every session, every speaker, every format choice is oriented around one thing: real-world evidence.

That focus changes the quality of the room. When 200-plus senior professionals all work in the same discipline, the conversations in the coffee breaks are as valuable as the sessions themselves.

What’s on the RWE Connect’s agenda?

The RWE speakers are decision-makers, not placeholders.

Heads of Global HEOR. RWE Directors. Epidemiology leads. VP-level market access professionals. These are not people who were sent because the budget holder could not make it. They are the budget holders. Confirmed participants include senior leaders from Gilead Sciences, Boehringer Ingelheim, BioMarin, Novo Nordisk, Bayer, and Alcon.

The format is built for outcomes, not optics.

The Partnering Lounge runs structured 1:1 meetings. Pre-scheduled, private, purposeful. Not a networking cocktail hour where you trade business cards with someone whose badge you cannot read. Masterclass workshops are hands-on. You leave with frameworks you can apply on Monday morning.

The Startup Pavilion shows you what the next generation of RWE tools looks like before your competitors have evaluated them.

Boston is not a coincidence.

The Greater Boston area is home to hundreds of biopharma headquarters, R&D centres, and innovation hubs. Harvard, MIT, and the city’s academic medical centres feed the attendee list with scientific credibility. Leading RWD companies, including Truveta, Forian, and Arcadia, are active in this market. The location maximises the concentration of the right people in one room. Check out our sponsors.

Register for RWE Connect 2026 today →